Xvivo Perfusion AB (0RKL) AI Stock Analysis

Xvivo Perfusion AB

(LSE:0RKL)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong organic growthThe broad-based growth indicates rising adoption of XVIVO’s transplantation technologies, especially in thoracic procedures. Strong sales expansion across the first nine months supports operating leverage, funds continued commercial investment, and strengthens the company’s position as transplant centers adopt advanced preservation workflows.

Negative Factors

Component constraintsComponent shortages directly limit the company’s ability to convert customer demand into revenue, particularly in kidney products. Although management describes the issue as temporary, continued constraints over coming quarters could delay growth, weaken customer availability, and postpone the return to higher growth rates.

Xvivo Perfusion AB (0RKL) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 682.91M
Dividend Yield: ―
Average Volume (3M): 7,495
Price to Earnings (P/E): 50.1
Beta (1Y): 1.44
Revenue Growth: 17.83%
EPS Growth: 330.94%
Country: UK
Employees: 207
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Xvivo Perfusion AB Business Overview & Revenue Model

Company Description

Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across S...

Xvivo Perfusion AB Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:-12.22%|Next Earnings Date:Jan 27, 2027

Earnings Call SentimentPositive

The call was strongly positive overall, with 32% organic Q3 growth, improving EBITDA and cash flow, strong thoracic and heart momentum, major European and U.S. regulatory progress, and multiple expansion opportunities. The main challenges were temporary component and manufacturing-transfer constraints, weaker services revenue and margins, uncertainty around a major U.S. lung customer, reimbursement timing in Europe, competition in U.S. Liver, and planned near-term commercial investment that is expected to cause a slight margin dip.

Positive Updates

Strong Q3 Revenue and EBITDA Growth

Q3 net sales reached SEK 253 million, representing 32% organic growth in local currencies. EBITDA increased to SEK 52 million from SEK 36 million, and the EBITDA margin improved to 21% from 19%, supported primarily by strong sales and seasonally lower summer activity levels on the cost side.

Negative Updates

Temporary Headwind from Component Transition

Sales in the current and coming quarters will be affected by the transition to updated core components. Management described this as a temporary headwind, and stated that component shortages will prevent XVIVO from fulfilling the full market demand for kidney products next year.

Company Guidance

Management said kidney growth would be “moderate growth, probably around 30%” next year, although component shortages mean XVIVO “will not be able to fulfill the full demand of the market next year in kidney,” with growth expected to “return to higher levels of growth from the beginning of 2027”; service growth in 2027 is “very reasonable to expect,” “not necessarily in Q4”; new lung customer growth will “hopefully cover any shortfall,” which is the “working hypothesis right now”; static cold storage growth is expected to be “roughly 5% for next year”; Tier 2 heart customers are targeted for onboarding in December, with a “three to four months” listing process; the U.S. Heart Assist Transport commercial launch is targeted for “late 2027,” subject to the FDA review process and approval; Liver Assist is targeted for a 510(k) submission in “the first half of 2027” and a commercial launch in “early 2028,” subject again to regulatory timelines; and management expects “a slight margin dip during the second half of the year” from increased sales-force investment.

Xvivo Perfusion AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0RKL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:GETI.B	67Neutral	SEK 75.64B	26.73	9.13%	1.71%	-3.90%	37.73%
SE:VITR	61Neutral	SEK 15.64B	-3.15	-61.57%	0.95%	-1.94%	-1223.74%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:SEDANA	49Neutral	SEK 926.81M	-26.86	-3.88%	―	0.42%	15.03%
SE:BICO	48Neutral	SEK 1.73B	-2.06	-49.84%	―	-15.45%	-164.23%
SE:SCIB	39Underperform	SEK 174.38M	-0.78	-303.61%	―	51.21%	42.24%

* General Sector Average

Performance Comparison

GB:0RKL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0RKL	Xvivo Perfusion AB	207.60	24.45	13.35%
SE:GETI.B	Getinge AB (UK)	277.70	60.83	28.05%
SE:VITR	Vitrolife AB	115.50	-26.84	-18.85%
SE:BICO	BICO Group AB Class B	24.45	3.45	16.43%
SE:SCIB	SciBase Holding AB	12.35	-13.24	-51.74%
SE:SEDANA	Sedana Medical AB	9.33	-0.83	-8.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Xvivo Perfusion AB AI Stock Analysis